The Application of Peptides in Glioma: A Novel Tool for Therapy
Authors:
- 1 April 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (5) , 620-633
Abstract
Background: Glioma is the most aggressive and lethal tumor of the central nervous system. Due to the cellular heterogeneity, the invasiveness, and blood-brain barrier (BBB), current therapeutic approaches, such as chemotherapy and radiotherapy, are poorly to obtain great anti-tumor efficacy. However, peptides, a novel type of therapeutic agent, displayed excellent ability in the tumor, which becomes a new molecule for glioma treatment.Method: We review the current knowledge on peptides for the treatment of glioma through a PubMed-based literature search.Results: In the treatment of glioma, peptides can be used as (i) decoration on the surface of the delivery system, facilitating the distribution and accumulation of the anti-tumor drug in target site;(ii) anti-tumor active molecules, inhibiting the growth of glioma and reducing solid tumor volume; (iii) immune-stimulating factor, and it activating immune cells in the tumor microenvironment or recruiting immune cells to the tumor for breaking out the immunosuppression by glioma cells.Conclusion: The application of peptides has revolutionized the treatment of glioma, which based on targeting, penetrating, anti-tumor activities and immunostimulatory. Moreover, better outcomes have been discovered in combining different kinds of peptides rather than a single one. Until now, more and more preclinical studies have been developed with multifarious peptides, which shows promising results in vitro or vivo with the model of glioma.Keywords
Funding Information
- National Science and Technology Major Project (2018ZX09J18109-005)
- Science and Technology Achievements Transformation Fund Project of Third Military Medical University (2015XZH19)
This publication has 157 references indexed in Scilit:
- Establishment of a simplified in vitro porcine blood–brain barrier model with high transendothelial electrical resistanceBrain Research, 2013
- The effect of functionalizing lipid nanocapsules with NFL-TBS.40-63 peptide on their uptake by glioblastoma cellsBiomaterials, 2013
- Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viabilityProceedings of the National Academy of Sciences, 2011
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Antiangiogenic therapy in brain tumorsExpert Review of Neurotherapeutics, 2008
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case studyNeuro-Oncology, 2008
- Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cellsBrain Research, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinomaOncogene, 2004